Sangrix Inc. SGRX
Finance: Consumer Services · IPO 2019 · data as of November 13, 2026
Sangrix Inc. (SGRX) is a financial company listed in the US with a market value of about $131806.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -112%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
About Sangrix
Sangrix is listed in the US and classified in finance: consumer services, IPO year 2019. Revenue went from $63M in 2017 to $39495 in 2025, a decline of about 60.2% a year. It was profitable in 4 of the last 10 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $39495 | $3M | $6M | $6M | $80M | $24M | $99M | $101M | $63M |
| Net income | -$24M | -$7M | -$18M | -$28M | $3M | -$46M | -$5M | $4M | $4M | $2M |
| Free cash flow | — | — | — | -$7M | -$23M | — | -$7M | -$5M | -$4M | -$3M |
| EPS (diluted) | $-65.71 | $-17.95 | $-48.15 | $-77.49 | $8.90 | $-125.26 | $-13.39 | $11.98 | $10.35 | $6.74 |
| Net margin | — | -16543.8% | -606.9% | -450.7% | 51.7% | -56.7% | -20.1% | 4.4% | 3.7% | 3.9% |
| ROIC | -200.7% | -18.7% | -93.7% | -180.9% | -64.5% | -32.3% | -9.1% | -1.7% | 31.3% | 25.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Sangrix stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sangrix pay a dividend?
Not currently.
Is Sangrix a good stock to buy?
We do not give buy or sell advice. Sangrix scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.